AKESO

9926
64.10022.11% ( -18.200 )
Delay Closed: Nov 16, 16:08:11

Overview

AKESO (9926)

Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company deve...

Open
70.000
High
70.000
Low
56.100
Prev. Close
82.300
Volume
70.84M
Turnover
4.41B
Avg Price
62.270
Bid/Ask Ratio
-90.00%
Amplitude
16.89%
52wk High
156.000
Volume Ratio
5.58
Turnover Ratio
7.53%
52wk Low
56.100
HK Mkt Cap
60.33B
Market CapHKD
60.33B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-1.18
EPSDynamic
-1.04
EPSStatic
--
BVPS
10.38
P/B
6.17
HK Shares
941.14M
Dividend YieldTTM
--
DividendTTM
--
Shares
941.14M
Min lot size
1,000
Currency
HKD

AKESO Analyst Rating

View more

Forecast & Rating

Nov 16, 2026
Price forecast
HK$147.88130.71%
Forecast & RatingStrong buy
23analysts
  • Strong buy73.91%
  • Buy17.39%
  • Hold8.70%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    Akeso Biotech sank 22% to HKD 64.10 today, primarily driven by FDA's rejection of ivonescimab, a lung cancer drug developed with partner Summit Therapeutics, for U.S. market approval. The stock plunged to HKD 56.10 during intraday trading, marking a fresh 52-week low, before buyers returned to lift it to HKD 64.85 by afternoon's end. Citi and Nomura subsequently cut their target prices to HKD 163 and HKD 94 respectively, reflecting market reassessment of this clinical setback. Positively, gumokimab secured regulatory approval in China for active ankylosing spondylitis, and recent quarters demonstrated revenue growth surpassing 35%. Nevertheless, the company remains unprofitable, with Q2 posting a net loss of HKD 244.9 million. From a price-position perspective, the stock has tumbled 43.42% since year-start and trades 59% below its 52-week peak of HKD 156, having recovered only 14% from yesterday's 52-week nadir, signaling fragile investor sentiment.

  2. Nov, 13

    Akeso slid 3.9% to HKD 82.30, dragged by a nearly 1% Hang Seng decline amid market weakness. Recent ivonescimab data—achieving 50.7% pathological complete response in lung cancer trials and securing priority review for first-line biliary tract cancer—had fueled an 8% weekly run, but profit-taking emerged today. Q2 revenues rose 34.84% year-over-year to HKD 1.043 billion, while net losses of HKD 245 million improved 21.56%. Trading 27.36% below year-start levels, the stock sits well below its 20-day (HKD 85.35) and 60-day (HKD 93.00) moving averages, and 47% below the 52-week high of HKD 156, having rebounded roughly 10% from early November's low but lacking sustained upside momentum.

  3. Nov, 12

    Akeso Pharmaceuticals dipped roughly 3.3% to HK$85.65, primarily driven by profit-taking following its rebound from the 52-week low of HK$74.5 reached in early November. On the positive front, ivonescimab demonstrated a 50.7% pathological complete response rate in a Phase II lung cancer trial, while securing priority review in China for first-line biliary tract cancer treatment, signaling solid momentum in its pipeline. Q2 revenue reached HK$10.43 billion, growing 34.84% year-over-year, though net loss stood at HK$245 million with a net loss margin of -23.49%, representing a 21.56% improvement from the prior year. Valuationally, the stock has declined 24.4% year-to-date and remains 45.1% below its 52-week high of HK$156, trading just below the 20-day moving average of HK$85.755 and significantly below the 60-day moving average of HK$93.12. While the recent rebound from historical lows is encouraging, converting clinical progress into meaningful revenue growth and profitability will require sustained validation in larger trials and market adoption.

  4. Nov, 11

    Akeso Pharma's stock dipped 0.56% to HK$88.6 today despite recent product progress, as market skepticism over the path to profitability weighs on valuation. Year-to-date the stock has fallen 21.8% from HK$113.3 and sits 43.21% below the 52-week high of HK$156 set in mid-April, though it has rebounded 18.93% from the 52-week low of HK$74.5 hit just 9 days ago. Q2 revenue surged to HK$1.04B with 34.84% YoY growth and losses narrowing 21.56% YoY; EPS came in at HK$-0.27 but showed sequential improvement, indicating accelerating commercialization. Lead asset ivonescimab demonstrated 50.7% pathological complete response in Phase II lung cancer trials and secured NMPA priority review for biliary tract cancer. However, persistent negative net margin at -23.49%, thin trading with turnover of only 0.66%, and the stock trading below its 60-day moving average of HK$93.2 underscore investor caution on the path to profitability.

  5. Nov, 9

    Akeso surged about 4% today, driven by positive clinical progress of ivonescimab in biliary tract cancer. The lead program achieved a 50.7% pathological complete response rate in Phase II and demonstrated a 25% reduction in death risk in Phase III trials, while also securing priority review status from regulators. These achievements bolstered market confidence. Trading activity showed the stock climbing to 91.65 HKD in the morning session before settling at 88.7 HKD at the close. However, the company remains down 21.71% year-to-date and trades 43.14% below its 52-week high of 156 HKD, well below its 60-day moving average of 93.36 HKD. Recent quarterly revenues maintained roughly 35% year-over-year growth, though the company continues operating at a net loss as it scales its drug pipeline toward profitability.

News

Bullish vs. Bearish — Last 3 Months

13.7k followers · 0 opinions
▲Bullish50%
50%Bearish▼
  • K
    kailash

    Anthropic's massive valuation target alongside a $42B loss shows that AI infrastructure spending is still going full throttle, regardless of high costs. It's a high-stakes game where only the strongest will survive in the long run

    C
    Captain's Watch
    Featured☕️ [Task Coins Giveaway] Daily Market Talk — Anthropic's IPO Filing Reveals a $42B Loss

    Reuters got a first look at Anthropic's IPO prospectus: revenue up 12-fold, a $42 billion net loss, and a $2 trillion valuation target. Meanwhile Treasury yields hit fresh multi-decade highs and gold ...

  • N
    NewUser_hCn26

    Anthropic’s massive $42 billion loss highlights the immense capital intensity of frontier AI models. A $2 trillion valuation target amid soaring Treasury yields forces a stark choice: pay a premium for hyper-growth scale or wait until multi-decade rate pressure forces financial discipline across unproven, capital-hungry balance sheets.

    C
    Captain's Watch
    Featured☕️ [Task Coins Giveaway] Daily Market Talk — Anthropic's IPO Filing Reveals a $42B Loss

    Reuters got a first look at Anthropic's IPO prospectus: revenue up 12-fold, a $42 billion net loss, and a $2 trillion valuation target. Meanwhile Treasury yields hit fresh multi-decade highs and gold ...

  • 0
    0wMYbg

    I wouldn’t buy into Anthropic’s IPO yet since the company has such high net loss now, shall stay on the sidelines and see what happens.

    C
    Captain's Watch
    Featured☕️ [Task Coins Giveaway] Daily Market Talk — Anthropic's IPO Filing Reveals a $42B Loss

    Reuters got a first look at Anthropic's IPO prospectus: revenue up 12-fold, a $42 billion net loss, and a $2 trillion valuation target. Meanwhile Treasury yields hit fresh multi-decade highs and gold ...